Clinical Trial Update: A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa [Phase 3]

View source ↗

Summary

Ocugen reports a Phase 3 trial of the OCU400 gene therapy for retinitis pigmentosa is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• OCU400

Snippet

Sponsor: Ocugen | Conditions: Retinitis Pigmentosa | Phase 3 | Status: ACTIVE_NOT_RECRUITING